Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment.We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n ؍ 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status.We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and downstream proteins.Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type.To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines.EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue.Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant.These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor  suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage.This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.Molecular & Cellular Proteomics 7:1902-1924, 2008.The phenotype of an individual patient's cancer is a product of the somatic genetic mutations underlying the tumor.One or more of these genetic changes provides a survival advantage for the cancer cells in the context of the tissue microenvironment.Thus, at a functional level, protein-mediated signaling is directly and indirectly influenced by both the genetic underpinnings and the microecology of the tumor.The "oncogene addiction theory" postulates that genetic mutations cause an oncogenic protein to dominate the signaling control of the cancer cell clone, thereby driving it to survive, grow, invade, and metastasize (1, 2).Mutations in the ERBB 1 family of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 4×
“EGFR signaling involves five distinct steps: 1) ligand binding, 2) conformational change in the receptor, 3) homodimerization and/or heterodimerization with other ERBB family receptors, 4) autophosphorylation of tyrosine residues, and 5) transphosphorylation of downstream kinases (16, 46).”
BackgroundInfluentialShigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
Gual, P., Le Marchand-Brustel, Y., & Tanti, J.-F. (2005) · Biochimie · doi:10.1016/j.biochi.2004.10.019 · Cited by 912 · cited 16×
“These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced r…”
BackgroundInfluentialA rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214
Stimulus Design for Model Selection and Validation in Cell Signaling
Apgar, J. F., Toettcher, J. E., Endy, D., White, F. M., & Tidor, B. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0040030 · Cited by 79
Cited by
Protein Analysis by Shotgun/Bottom-up Proteomics
Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C., & Yates, J. R. (2013) · Chemical Reviews · doi:10.1021/cr3003533 · Cited by 1,491
Wei, Y., Zou, Z., Becker, N., Anderson, M., Sumpter, R., Xiao, G., Kinch, L., Koduru, P., Christudass, C. S., Veltri, R. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.015 · Cited by 505
Biasutto, L., Chiechi, A., Couch, R., Liotta, L. A., & Espina, V. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.05.005 · Cited by 126
Self-citation
Metadata
- Authors
- VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J., Harris, C. C., Deng, J., Calvert, V. S., Silvestri, A., Fredolini, C., Chandhoke, V., Petricoin, E. F., Liotta, L. A., & Espina, V.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 7
- Issue
- 10
- Pages
- 1902-1924
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2022210208
- Cited by
- 105
- References
- 9
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. https://app.cochat.ai/papers/10.1074/mcp.m800204-mcp200
- The paper
- VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J., Harris, C. C., Deng, J., Calvert, V. S., Silvestri, A., Fredolini, C., Chandhoke, V., Petricoin, E. F., Liotta, L. A., & Espina, V. (2008). Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular & Cellular Proteomics. https://doi.org/10.1074/mcp.m800204-mcp200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.